Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP621010.RAhysOM1nbe2l9M1OdDHjUoT3csK0E1IcM8X1omFNC4Ts130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP621010.RAhysOM1nbe2l9M1OdDHjUoT3csK0E1IcM8X1omFNC4Ts130_assertion type Assertion NP621010.RAhysOM1nbe2l9M1OdDHjUoT3csK0E1IcM8X1omFNC4Ts130_head.
- NP621010.RAhysOM1nbe2l9M1OdDHjUoT3csK0E1IcM8X1omFNC4Ts130_assertion description "[Class I phosphoinositide 3-kinases (PI3K) have been extensively studied in different models these last years and several isoforms are now promising drug targets to treat cancer and immune diseases.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP621010.RAhysOM1nbe2l9M1OdDHjUoT3csK0E1IcM8X1omFNC4Ts130_provenance.
- NP621010.RAhysOM1nbe2l9M1OdDHjUoT3csK0E1IcM8X1omFNC4Ts130_assertion evidence source_evidence_literature NP621010.RAhysOM1nbe2l9M1OdDHjUoT3csK0E1IcM8X1omFNC4Ts130_provenance.
- NP621010.RAhysOM1nbe2l9M1OdDHjUoT3csK0E1IcM8X1omFNC4Ts130_assertion SIO_000772 24095650 NP621010.RAhysOM1nbe2l9M1OdDHjUoT3csK0E1IcM8X1omFNC4Ts130_provenance.
- NP621010.RAhysOM1nbe2l9M1OdDHjUoT3csK0E1IcM8X1omFNC4Ts130_assertion wasDerivedFrom befree-20150227 NP621010.RAhysOM1nbe2l9M1OdDHjUoT3csK0E1IcM8X1omFNC4Ts130_provenance.
- NP621010.RAhysOM1nbe2l9M1OdDHjUoT3csK0E1IcM8X1omFNC4Ts130_assertion wasGeneratedBy ECO_0000203 NP621010.RAhysOM1nbe2l9M1OdDHjUoT3csK0E1IcM8X1omFNC4Ts130_provenance.